Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke

被引:219
作者
Maulaz, AB [1 ]
Bezerra, DC [1 ]
Michel, P [1 ]
Bogousslavsky, J [1 ]
机构
[1] CHU Vaudois, Dept Neurol, CH-1011 Lausanne, Switzerland
关键词
D O I
10.1001/archneur.62.8.1217
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Aspirin, or acetylsalicylic acid, is widely used to prevent ischemic vascular disease. Clinical and experimental data suggest that a rebound effect occurs 4 or fewer weeks after interruption of aspirin therapy. Objective: To study the discontinuation of aspirin therapy as a risk factor for ischemic stroke (IS). Design: Case-control study. Setting: Stroke unit. Participants: Three hundred nine patients with IS or transient ischemic attack undergoing long-term aspirin treatment before their index event and 309 age-, sex-, and antiplatelet therapy-matched controls who had not had an IS in the previous 6 months. Methods: We compared the frequency of aspirin therapy discontinuation during the 4 weeks before an ischemic cerebral event in patients and the 4 weeks before interview in controls. Results: The 2 groups had a similar frequency of risk factors, except for coronary heart disease, which was more frequent in patients (36% vs 18%; P < .001). Aspirin use had been discontinued in 13 patients and 4 controls. Aspirin interruption yielded an odds ratio for IS/transient ischemic attack of 3.4 (95% confidence interval, 1.08-10.63; P < .005) after adjustment in a multivariable model. Conclusions: These results highlight the importance of aspirin therapy compliance and give an estimate of the risk associated with the discontinuation of aspirin therapy in patients at risk for IS, particularly those with coronary heart disease.
引用
收藏
页码:1217 / 1220
页数:4
相关论文
共 22 条
[1]   Thromboembolic complications several days after a single-dose administration of aspirin [J].
Aguejouf, O ;
Belougne-Malfatti, E ;
Doutremepuich, F ;
Belon, P ;
Doutremepuich, C .
THROMBOSIS RESEARCH, 1998, 89 (03) :123-127
[2]   Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy [J].
Alam, M ;
Goldberg, LH .
DERMATOLOGIC SURGERY, 2002, 28 (11) :992-998
[3]   Acute stent thrombosis after early withdrawal of platelet glycoprotein IIb/IIIa antagonists:: Potential rebound prothrombotic effect? [J].
Angiolillo, DJ ;
Sabaté, M ;
Fernández-Ortiz, A ;
Macaya, C .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2003, 58 (04) :481-484
[4]   Discontinuing chronic aspirin therapy: Another risk factor for stroke? [J].
Bachman, DS .
ANNALS OF NEUROLOGY, 2002, 51 (01) :137-138
[5]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[6]   INTERINDIVIDUAL VARIATIONS OF THE EFFECT OF LOW-DOSE ASPIRIN REGIME ON PLATELET CYCLOOXYGENASE ACTIVITY [J].
BEVING, H ;
EKSBORG, S ;
MALMGREN, RS ;
NORDLANDER, R ;
RYDEN, L ;
OLSSON, P .
THROMBOSIS RESEARCH, 1994, 74 (01) :39-51
[7]   Role of inflammation in stroke and atherothrombosis [J].
Chamorro, A .
CEREBROVASCULAR DISEASES, 2004, 17 :1-5
[8]   Myocardial infarction after aspirin cessation in stable coronary artery disease patients [J].
Collet, JP ;
Himbert, D ;
Steg, PG .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2000, 76 (2-3) :257-258
[9]   Cerebral ischemia: New risk factors [J].
Diaz, J ;
Sempere, AP .
CEREBROVASCULAR DISEASES, 2004, 17 :43-50
[10]   ARTERIAL THROMBOSIS IN THE NEPHROTIC SYNDROME [J].
FAHAL, IH ;
MCCLELLAND, P ;
HAY, CRM ;
BELL, GM .
POSTGRADUATE MEDICAL JOURNAL, 1994, 70 (830) :905-909